Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ETHACRYNATE SODIUM vs BUMETANIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.
Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Treatment of edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema,Off-label: Adjunct in treatment of acute hypercalcemia
Edema associated with congestive heart failure, hepatic cirrhosis, and renal disease,Treatment of hypertension (off-label)
50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.
0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.
Terminal elimination half-life: 2-4 hours in normal renal function; prolonged to 20-30 hours in end-stage renal disease.
Terminal elimination half-life is approximately 1-1.5 hours in healthy adults; prolonged to 1.5-3 hours in renal impairment.
Primarily metabolized by hepatic glutathione S-transferase (GST) to a cysteine conjugate; minor metabolism via oxidation. Excreted in urine and bile.
Primarily metabolized by the liver via cytochrome P450 (CYP) enzymes, with approximately 50% excreted unchanged in urine.
Renal: approximately 30% unchanged; biliary/fecal: minor (less than 10%); majority metabolized to cysteine adducts excreted in urine.
Primarily renal (approximately 80% as unchanged drug), with minimal biliary/fecal excretion (about 10-20%).
Approximately 95% bound, primarily to albumin.
Approximately 95% bound, primarily to albumin.
0.1-0.2 L/kg (small Vd, consistent with high protein binding and limited extravascular distribution).
0.15-0.25 L/kg; indicates limited extravascular distribution, consistent with high protein binding.
Oral: approximately 100% (well absorbed, no significant first-pass metabolism).
Oral: approximately 80-100% (mean ~90%), with a first-pass effect of about 10-20%.
e GFR 30-59 m L/min: reduce dose by 50%; e GFR <30 m L/min: avoid use or use with extreme caution.
No specific dose adjustment for GFR >20 m L/min. For GFR 10-20 m L/min: use with caution, dose every 12-24 hours. For GFR <10 m L/min: not recommended due to lack of efficacy.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
1 mg/kg intravenously once daily; maximum 50 mg/day. Not recommended in neonates.
IV/IM/PO: 0.015-0.1 mg/kg/dose every 6-24 hours; max 10 mg/day. For neonates: 0.01-0.05 mg/kg/dose every 12-24 hours.
Start at 25 mg intravenously once daily; increase slowly due to increased risk of electrolyte disturbances and hypotension.
Start at 0.5 mg once daily; titrate cautiously due to increased sensitivity and risk of electrolyte imbalance and volume depletion.
Ethacrynic acid (ethacrynate) can cause profound diuresis with water and electrolyte depletion; close medical supervision and dose titration are required.
Bumetanide is a potent diuretic that can lead to profound diuresis with water and electrolyte depletion. Close medical supervision and dose titration are required. Excessive doses can lead to hypovolemia, dehydration, and circulatory collapse.
May cause severe electrolyte disturbances (hypokalemia, hyponatremia, hypochloremia) and volume depletion,Ototoxicity, especially with rapid IV administration or in patients with renal impairment; may be irreversible,Hyperuricemia and gout,Hepatic coma can be precipitated in patients with cirrhosis or ascites,May increase risk of digoxin toxicity due to hypokalemia,Photosensitivity reaction possible
Monitor fluid and electrolyte balance closely,Risk of ototoxicity, especially at high doses or with rapid infusion,May cause hyperuricemia and precipitate gout attacks,Can increase risk of digitalis toxicity due to hypokalemia
Anuria,Hypersensitivity to ethacrynic acid or any component,Severe electrolyte depletion (hypokalemia, hyponatremia, hypochloremia),Hepatic coma or precoma
Anuria,Severe electrolyte depletion,Hepatic coma or pre-coma,Hypersensitivity to bumetanide or sulfonamides
Avoid excessive intake of salt substitutes containing potassium unless advised by your doctor. Grapefruit juice may enhance diuretic effect; monitor for hypotension. Alcohol can increase diuretic effect and risk of hypotension. Caffeine may worsen electrolyte imbalance. Ensure adequate fluid intake unless fluid restriction is prescribed.
No specific food restrictions, but limit salt intake to help control edema and hypertension. Avoid excessive intake of black licorice (can worsen hypokalemia). Grapefruit juice may not significantly interact, but caution with any electrolyte-altering foods. Maintain adequate fluid intake unless fluid restriction is advised by your doctor. Foods high in potassium (bananas, oranges, spinach) may be recommended if hypokalemia occurs; consult provider for individual needs.
Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, ototoxicity, and oligohydramnios in the fetus due to diuretic effect. Avoid use in pregnancy unless clearly needed.
Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk of electrolyte imbalances and hypovolemia in the fetus; possible oligohydramnios. Avoid use during pregnancy unless benefits outweigh risks.
Excreted into breast milk in low concentrations; M/P ratio not determined. Potential for adverse effects in nursing infants (e.g., electrolyte imbalance, diuresis). Weigh benefits against risks; consider alternative diuretics.
Bumetanide is excreted into human milk in small amounts (M/P ratio not determined). Due to potential for diuresis in the infant, use with caution, especially in neonates. Consider alternative agents with more safety data.
Pregnancy may alter pharmacokinetics due to increased plasma volume and renal clearance; however, specific dose adjustments for ethacrynate sodium are not established. Use lowest effective dose and monitor for hypotension and electrolyte imbalances.
Pregnancy may increase volume of distribution and renal clearance, potentially requiring higher doses. However, starting dose is generally unchanged; titration based on response and tolerability. Monitor for hypokalemia and hypovolemia.
Ethacrynate sodium is a loop diuretic used for patients with sulfonamide allergy as it is not a sulfonamide derivative. Monitor for ototoxicity, especially in patients with renal impairment or when used with other ototoxic drugs. Rapid IV administration can cause severe hypotension; infuse slowly over several minutes. Hypokalemia and hypomagnesemia are common; monitor electrolytes and consider potassium-sparing diuretic or supplementation. Ethacrynic acid can cause GI bleeding; use with caution in peptic ulcer disease.
Bumetanide is a potent loop diuretic with rapid onset and short duration. Oral bioavailability is ~80% with minimal first-pass metabolism. Onset of diuresis within 30-60 minutes, peak at 1-2 hours, duration 4-6 hours. For acute pulmonary edema, intravenous bumetanide can be given 0.5-1 mg; onset within minutes. Monitor electrolytes especially potassium, magnesium, and calcium due to increased excretion. May cause ototoxicity, especially with rapid IV administration or concurrent aminoglycosides. Use with caution in sulfonamide allergy (cross-sensitivity). In renal impairment, bumetanide may be less effective due to reduced tubular secretion; higher doses may be needed. Combine with thiazides for sequential nephron blockade in resistant edema.
Take this medication exactly as prescribed, usually once or twice daily.,You may need to urinate frequently; take your last dose of the day early to avoid nighttime urination.,Avoid alcohol and limit salt intake to help reduce fluid retention.,Report any hearing loss, ringing in the ears, or dizziness to your healthcare provider immediately.,Eat potassium-rich foods like bananas, oranges, or potatoes unless directed otherwise by your doctor.,Weigh yourself daily and report sudden weight gain or loss to your healthcare provider.,Do not take any over-the-counter medications, especially NSAIDs, without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose. Do not double the dose.
Take bumetanide exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not skip doses or double up on missed doses; if you miss a dose, take it as soon as you remember unless it is almost time for the next dose.,This medication can cause dehydration and electrolyte imbalances; notify your doctor if you experience excessive thirst, dry mouth, weakness, muscle cramps, or irregular heartbeat.,Avoid alcohol and over-the-counter medications, especially NSAIDs (ibuprofen, naproxen) unless approved by your doctor, as they may reduce bumetanide's effectiveness and increase kidney risk.,Stand up slowly from sitting or lying to prevent dizziness from low blood pressure.,Monitor your weight daily and report rapid weight gain or loss to your healthcare provider.
No interactions on record
"Concurrent use of bumetanide, a loop diuretic, and allopurinol, a xanthine oxidase inhibitor, may increase the risk of allopurinol hypersensitivity reactions, including Stevens-Johnson syndrome and acute gout flares. This interaction is thought to result from bumetanide-induced volume depletion and reduced renal clearance of oxypurinol, the active metabolite of allopurinol, leading to elevated serum oxypurinol levels and enhanced toxicity. Clinically, patients may present with rash, fever, eosinophilia, or acute gouty arthritis, particularly in those with renal impairment."
"Fenbufen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits renal prostaglandin synthesis, which can reduce the efficacy of loop diuretics like bumetanide by blunting the diuretic-induced increase in renal blood flow and sodium excretion. This pharmacodynamic antagonism may result in diminished diuresis and natriuresis, potentially exacerbating fluid overload in patients with heart failure or hypertension. Clinically, this interaction may lead to suboptimal blood pressure control or worsening edema if the combination is used without dose adjustment."
"Concurrent administration of apomorphine, a dopamine agonist used for Parkinson's disease, with bumetanide, a loop diuretic, may lead to an increased risk of adverse effects, particularly hypotension and syncope. Apomorphine is known to cause orthostatic hypotension due to its vasodilatory and dopaminergic effects, which can be potentiated by bumetanide-induced volume depletion and electrolyte disturbances. This interaction can result in profound blood pressure drops, dizziness, and potential falls, especially in elderly patients or those with already compromised cardiovascular status."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ETHACRYNATE SODIUM vs BUMETANIDE, answered by our medical review team.
ETHACRYNATE SODIUM is a Loop Diuretic that works by Ethacrynate sodium inhibits the Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased diuresis.. BUMETANIDE is a Loop Diuretic that works by Inhibits the Na-K-2Cl symporter (NKCC2) in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ETHACRYNATE SODIUM and BUMETANIDE depend on the specific clinical indication. These are both Loop Diuretic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ETHACRYNATE SODIUM is: 50 mg intravenously once daily; may increase in increments of 25-50 mg as needed, maximum 200 mg/day.. The standard adult dose of BUMETANIDE is: 0.5-2 mg IV/IM/PO once daily; may repeat every 6-8 hours; max 10 mg/day. Continuous IV infusion: 1 mg loading dose, then 0.5-2 mg/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ETHACRYNATE SODIUM and BUMETANIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ETHACRYNATE SODIUM is classified as Category C. Ethacrynate sodium crosses the placenta. First trimester: Limited human data; animal studies not available. Second and third trimesters: Potential for electrolyte disturbances, oto. BUMETANIDE is classified as Category A/B. Bumetanide crosses the placenta. First trimester: No adequate human studies; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: Risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.